Want to see SE:ANNX full AI Analyst Report?

Annexin Pharmaceuticals AB (ANNX) Price & Analysis

2 Followers

ANNX Stock Chart & Stats

kr13.65

kr0.01(3.44%)

At close: Mar 06 4:00 PM EST

kr13.65

kr0.01(3.44%)

Day’s Range― - ―

52-Week Rangekr11.05 - kr29.36

Previous CloseN/A

Volume76.75K

Average Volume (3M)7.16K

Market Cap

kr109.41M

Enterprise Valuekr81.08

Total Cash (Recent Filing)kr5.27M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.96

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding8,718,182

10 Day Avg. Volume5,553

30 Day Avg. Volume7,155

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)5.25

Price to Sales (P/S)0.00

P/FCF Ratio-3.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance SheetThe absence of reported debt limits interest expense and reduces leverage-related financial risk while the company advances its pipeline. This provides greater flexibility than a highly indebted biotech, although it does not eliminate the need for future financing.

Focused Vascular PipelineA focused lead program targeting vascular injury and inflammation gives the company a defined development strategy rather than a broad, unfocused portfolio. Progress in these severe-disease indications could create future value if clinical and regulatory objectives are achieved.

Improving Cash BurnAlthough cash flow remains materially negative, the reduction in free-cash-flow burn versus 2024 indicates some improvement in cash usage. If sustained, better burn control could extend funding runway and moderate the pace of financing required to support development.

Bears Say

No Revenue GenerationZero reported revenue confirms that the company has not yet established a commercial income stream to fund operations. Until a product reaches the market or another recurring revenue source emerges, development spending remains dependent on capital raises and pipeline progress.

Persistent Operating LossesLarge ongoing operating and net losses show that the current business model is not yet profitable and has limited internal funding capacity. Continued losses can consume capital over the next several quarters, making results highly sensitive to clinical outcomes and financing access.

Capital Base ErosionThe sharp contraction in equity and assets indicates substantial erosion of the capital base from cumulative losses. This weakens financial resilience and raises the likelihood that additional external funding, potentially with dilution, will be needed to continue the development program.

ANNX FAQ

What was Annexin Pharmaceuticals AB’s price range in the past 12 months?

Annexin Pharmaceuticals AB lowest stock price was kr11.05 and its highest was kr29.36 in the past 12 months.

What is Annexin Pharmaceuticals AB’s market cap?

Annexin Pharmaceuticals AB’s market cap is kr109.41M.

When is Annexin Pharmaceuticals AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Annexin Pharmaceuticals AB’s earnings last quarter?

Currently, no data Available

Is Annexin Pharmaceuticals AB overvalued?

According to Wall Street analysts Annexin Pharmaceuticals AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Annexin Pharmaceuticals AB pay dividends?

Annexin Pharmaceuticals AB does not currently pay dividends.

What is Annexin Pharmaceuticals AB’s EPS estimate?

Annexin Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Annexin Pharmaceuticals AB have?

Annexin Pharmaceuticals AB has 8,718,182 shares outstanding.

What happened to Annexin Pharmaceuticals AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Annexin Pharmaceuticals AB?

Currently, no hedge funds are holding shares in SE:ANNX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.